~~<i id='C55BDEE89B'><strike id='C55BDEE89B'><tt id='C55BDEE89B'><pre id='C55BDEE89B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

fashion

author：comprehensive 2025-08-12 06:43:22 - browse：49149

Three sales executives, all of them women, have filed suit against Grail, a cancer diagnostics company, alleging that they were harassed, that the company failed to take corrective action, and that it retaliated by removing them from consideration for promotions.

The suits, which were filed earlier this week, are complicated by the fact that Grail was purchased by Illumina, the largest DNA sequencing firm, for $8 billion in 2021 — yet Illumina has left Grail to operate as a separate company. Illumina is named in the suit.

All three plaintiffs are being represented by the Vora Law Firm, based in Santa Monica, Calif.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Doctors find melanoma drugs effective against rare brain cancer

focus

leisure time

focus

entertainment

knowledge

explore

AP/RichardDrewJohnson&JohnsonsaidMondaythatitwouldpurchaseAmbrxBiopharmafornearly$2billion,picki

WSS

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

New weight loss drugs work. But how can they best be used?

J&J to buy cancer drug developer Ambrx Biopharma

Cosmetics set for new safety regulation. Why the industry is on board

The biotech scorecard for Q1: 17 stock

White House finalizes ITC's import ban of latest Apple Watches

hotspot

fashion

focus

Trump demands the U.S. pay no more for drugs than other countries … again

UCB departs biotech trade group BIO

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Federal weight loss drug coverage is 30 years out of date

Walensky prepares to leave CDC — and Congress — behind

Why hospitals are withdrawing from US News rankings

The high cost of giving birth even with insurance

Morgan Health, with ambitious aims, wants you to know it’s still here

Moonlake's readout produced a cash windfall. Risks remain

A single drug, study failures leave Anavex with nothing but cash

leisure time

STAT Virtual Event: The State of Biosimilars: What to Watch

New weight loss drugs work. But how can they best be used?

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

In early work, researchers turn to CRISPR to treat Alzheimer's

Ahead of JPM, here's who's profiting most in health care

Feng Zhang CRISPR delivery startup lays off quarter of staff

focus

entertainment

knowledge

explore